Filing Flows › AstraZeneca (AZN) › Q1 2026
AstraZeneca (AZN) Q1 2026 earnings results (first quarter 2026)
6-K filed Apr 29, 2026
AstraZeneca (AZN) reported revenue of $15.3B for the first quarter 2026 (Q1 2026), +13% from a year earlier. Operating margin was 27.8%, net earnings $3.1B (20.2% of revenue).
AstraZeneca, Q1 2026: revenue $15.3B (+12% year over year), operating margin 27.8%, net earnings $3.1B, operating cash flow $4.3B. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.3B | — | +13% |
| Gross profit | $12.6B | — | +11% |
| Operating profit | $4.2B | — | +16% |
| Net earnings | $3.1B | — | +5% |
| Operating cash flow | $4.3B | — | -4% |
| Free cash flow | $3.8B | — | -7% |
What changed
Revenue was $15.3B in Q1 2026, up 13% year over year. CVRM was the largest line at 21% of revenue.
Gross margin was 82.5%, down 1.0 points from a year earlier. Operating profit was $4.2B, a 27.8% margin (up 0.7 points year over year). Of the extra revenue versus a year earlier, 34% reached operating profit, above the 27% margin then. Operating expenses grew 9% against revenue growth of 13%. Net earnings were $3.1B, up 5% year over year. The effective tax rate was 21.3%.
Operating cash flow was $4.3B (down 4% year over year), 140% of net earnings. Working capital and other items added $1.2B. Capital expenditures of $0.55B left free cash flow of $3.8B.
Questions
What was AstraZeneca's revenue in the first quarter 2026?
AstraZeneca (AZN) reported revenue of $15.3B for the first quarter 2026 (Q1 2026), +13% from a year earlier.
Was AstraZeneca profitable in the first quarter 2026?
Operating profit was $4.2B (27.8% of revenue) and net earnings $3.1B.
Source: AstraZeneca 6-K on SEC EDGAR.